Isogenica, Biolauncher, Cresset in Discovery Platform Pact

The parties will integrate their expertise to identify active compounds against high-value therapeutic targets.

Isogenica, Biolauncher and Cresset Biomolecular Discovery have formed a collaborative joint venture to develop a discovery platform.

The parties will integrate their expertise in peptide library design, evolutionary screening, next generation sequencing, structural analytics and molecular field-based computational chemistry to identify active compounds against high-value therapeutic targets.